Jennison Associates LLC Takes Position in Disc Medicine, Inc. $IRON

Key Points

• Jennison Associates LLC bought a new stake of 532,079 shares in Disc Medicine (NASDAQ:IRON) in Q4, worth about $42.3 million, representing roughly 1.41% ownership; institutional investors now own about 83.7% of the company.
• Disc Medicine reported Q4 EPS of ($1.62), topping estimates by $0.07, while reported revenue was negative (~($19.9)M) versus consensus of $0.15M; analysts forecast FY EPS of -6.68.
• Wall Street sentiment is a "Moderate Buy" with a consensus price target of $104.80; the stock recently traded around $66.91 (52‑week range $40.00–$99.50) and has a market cap of about $2.55 billion.

Jennison Associates LLC purchased a new position in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 532,079 shares of the company's stock, valued at approximately $42,252,000. Jennison Associates LLC owned approximately 1.41% of Disc Medicine as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Aster Capital Management DIFC Ltd purchased a new stake in Disc Medicine in the 3rd quarter worth $38,000. KBC Group NV purchased a new stake in Disc Medicine in the 4th quarter worth $80,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Disc Medicine by 36.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,834 shares of the company's stock worth $146,000 after acquiring an additional 490 shares in the last quarter. Avanza Fonder AB increased its holdings in Disc Medicine by 14.1% in the 4th quarter. Avanza Fonder AB now owns 1,903 shares of the company's stock worth $151,000 after acquiring an additional 235 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in Disc Medicine by 15,137.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 2,438 shares of the company's stock worth $161,000 after acquiring an additional 2,422 shares in the last quarter. Hedge funds and other institutional investors own 83.70% of the company's stock.

Disc Medicine Trading Up 1.5%

Shares of IRON opened at $66.91 on Friday. Disc Medicine, Inc. has a 52-week low of $40.00 and a 52-week high of $99.50. The company has a quick ratio of 21.94, a current ratio of 21.94 and a debt-to-equity ratio of 0.04. The firm's fifty day moving average is $64.79 and its two-hundred day moving average is $76.14. The stock has a market cap of $2.55 billion, a PE ratio of -11.17 and a beta of 0.93.

Disc Medicine (NASDAQ:IRON - Get Free Report) last announced its earnings results on Thursday, February 26th. The company reported ($1.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.69) by $0.07. The business had revenue of ($19.88) million for the quarter, compared to analyst estimates of $0.15 million. Research analysts forecast that Disc Medicine, Inc. will post -6.68 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on IRON. Stifel Nicolaus cut their price target on shares of Disc Medicine from $125.00 to $110.00 and set a "buy" rating for the company in a report on Tuesday, February 17th. Wedbush cut their price target on shares of Disc Medicine from $110.00 to $88.00 and set an "outperform" rating for the company in a report on Tuesday, February 17th. Wall Street Zen raised shares of Disc Medicine from a "strong sell" rating to a "sell" rating in a report on Saturday, April 25th. Truist Financial cut their price target on shares of Disc Medicine from $114.00 to $83.00 and set a "buy" rating for the company in a report on Friday, February 27th. Finally, BMO Capital Markets cut their price target on shares of Disc Medicine from $120.00 to $100.00 and set an "outperform" rating for the company in a report on Tuesday, February 17th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Disc Medicine presently has an average rating of "Moderate Buy" and a consensus price target of $104.80.

Insider Activity

In other news, insider William Jacob Savage sold 7,378 shares of the business's stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $65.88, for a total transaction of $486,062.64. Following the transaction, the insider owned 85,211 shares of the company's stock, valued at approximately $5,613,700.68. The trade was a 7.97% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Jean M. Franchi sold 7,081 shares of the business's stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $65.47, for a total transaction of $463,593.07. Following the transaction, the chief financial officer directly owned 71,343 shares in the company, valued at approximately $4,670,826.21. The trade was a 9.03% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 59,410 shares of company stock worth $3,840,013. Insiders own 3.64% of the company's stock.

About Disc Medicine

Disc Medicine, Inc NASDAQ: IRON is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.